Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with  Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients…

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) #Lexicon039s #Drug #Discovery…

Rhythm Pharmaceuticals regains rights to obesity drug in China

Rhythm Pharmaceuticals regains rights to obesity drug in China#Rhythm #Pharmaceuticals #regains #rights #obesity #drug #China

Roche recruits Novo executive for obesity drug market entry – Bloomberg

Roche recruits Novo executive for obesity drug market entry – Bloomberg#Roche #recruits #Novo #executive #obesity #drug…

Gubra soars 23% on on AbbVie obesity drug licensing deal

Gubra soars 23% on on AbbVie obesity drug licensing deal#Gubra #soars #AbbVie #obesity #drug #licensing #deal

Obesity drug outlook: Hopes for stronger treatments, adherence remains a hurdle

Obesity drug outlook: Hopes for stronger treatments, adherence remains a hurdle#Obesity #drug #outlook #Hopes #stronger #treatments…

Scholar Rock: More Than Just SMA Biotech With Q2 2025 Obesity Treatment Data (NASDAQ:SRRK)

This article was written by Follow Terry Chrisomalis is a private investor in the Biotech sector…

Metsera Readies $275 Million IPO For Obesity Treatments

Metsera Readies $275 Million IPO For Obesity Treatments #Metsera #Readies #Million #IPO #Obesity #Treatments